ESMO 2023 | ESMO 2023: Key messages for breast cancer treatment

Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, shares his key takeaway messages with regard to breast cancer from the European Society for Medical Oncology (ESMO) 2023 Congress. He discusses the novel agents that are in development, such as additional Trop2-targeting antibody-drug conjugates and new endocrine therapies, as well as important studies such as the Phase III TROPION-Breast01 trial (NCT05104866), which compares datopotamab deruxtecan (data-DXd) to chemotherapy. This interview took place at the ESMO 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.